Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

BACKGROUND: Sorafenib is the first agent that has demonstrated an improved overall survival benefit in advanced hepatocellular carcinoma (HCC), setting a new standard for first-line treatment. However, no one has yet been able to predict sensitivity to sorafenib. Pre-treatment pERK level has been sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhe, Zhou, Xiaoyun, Shen, Hujia, Wang, Dexing, Wang, Yanhong
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738687/
https://www.ncbi.nlm.nih.gov/pubmed/19698189
http://dx.doi.org/10.1186/1741-7015-7-41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738687/
https://www.ncbi.nlm.nih.gov/pubmed/19698189
http://dx.doi.org/10.1186/1741-7015-7-41

Ejemplares similares